Transfusion-Associated Babesiosis after Heart Transplant by Lux, Joseph Z. et al.
DISPATCHES
116 Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003
Transfusion-
Associated
Babesiosis after
Heart Transplant
Joseph Z. Lux,* Don Weiss,† Jeanne V. Linden,‡ 
Debra Kessler,§ Barbara L. Herwaldt,¶ 
Susan J. Wong,‡ Jan Keithly,‡ Phyllis Della-Latta,# 
and Brian E. Scully*
We describe a 54-year-old spleen-intact man with transfu-
sion-associated Babesia microti infection after a heart trans-
plant. Adult respiratory distress syndrome developed in the
patient, and he required mechanical ventilation. Our experi-
ences with this patient suggest that babesiosis should be con-
sidered in the differential diagnosis of transplant patients who
have fever and hemolytic anemia.
abesiosis is a tick-borne protozoan illness caused by
infection of erythrocytes with various species in the genus
Babesia. In the United States, Babesia microti is the agent
most commonly reported to cause human infection (1). More
recently, the MO1-type, WA1-type, and CA1-type Babesia
species have been identified as causing clinical disease in the
United States (2–5). Babesia infection can also be acquired by
blood transfusion (2,6,7). More than 40 cases of transfusion-
transmitted  B. microti infection have been reported in the
United States (R. Cable and B. Herwaldt, unpub. data). B.
microti infection is often asymptomatic (8) but may cause a
malaria-like illness characterized by fever and hemolytic ane-
mia. Babesiosis can also be associated with severe complica-
tions that include renal failure (9,10), disseminated
intravascular coagulation (9), and adult respiratory distress
syndrome (1,9,10). The risk of developing this clinical infec-
tion is increased for elderly, asplenic, or immunosuppressed
patients (11). Here we describe a case of B. microti infection in
a 54-year-old spleen-intact man acquired by blood transfusion
after cardiac transplantation.
Case Report of Blood Recipient
The patient, a 54-year-old resident of New Jersey, had a
medical history of coronary artery disease and atrial fibrilla-
tion. Approximately 18 months before his transplant, a “bull’s-
eye” rash developed, and the patient was empirically treated
for Lyme disease. He did not recall a tick bite.
On August 19, 2000, he had an anterior wall myocardial
infarction and was hospitalized in his hometown. He required
intubation, placement of a coronary stent and an intra-aortic
balloon pump, use of intravenous cardiac inotropes, and trans-
fusion of 2 U of packed red blood cells (PRBC). When fever
developed, he was empirically treated with vancomycin, cipro-
floxacin, and metronidazole without improvement. No source
of infection was found. On September 6, he was transferred to
a New York City medical facility for placement of a left ven-
tricular assist device. Staphylococcus epidermidis was isolated
from two sets of blood cultures. He was then treated with van-
comycin and trimethoprim-sulfamethoxazole for 4 weeks. 
On September 26, the patient received an orthotopic car-
diac transplant. He received 32 U of irradiated leukocyte-
reduced PRBC, 23 U of fresh frozen plasma (FFP), 6 U of irra-
diated platelets, and 4 U of cryoprecipitate during his 5.5-week
hospital stay. On October 16, he was discharged on an immun-
osuppression regimen of cyclosporine, mycophenolate, and
prednisone.
On November 5, the patient became febrile. He was evalu-
ated by his cardiologist 3 days later. He had fever, chills, dia-
phoresis, headache, and sore throat. Blood and throat cultures
were obtained, as well as an endomyocardial biopsy specimen.
No source of infection or evidence of cardiac rejection was
found. 
On November 9, he was hospitalized again for evaluation
of continued fever. On admission, his temperature was
38.4×C. His surgical wound had healed well. Laboratory tests
showed a leukocyte count of 4.3 x 103/mm3 (83% neutrophils,
9% lymphocytes, 8% monocytes), hemoglobin concentration
of 11.4 g/dL, and a platelet count of 54,000/mm3. On Novem-
ber 10, the staff of the hospital parasitology laboratory identi-
fied intraerythrocytic ring forms and tetrads consistent with B.
microti infection on a peripheral blood smear; these results
were confirmed by the Centers for Disease Control and Pre-
vention (CDC). The parasitemia level was 1.6%. Indirect fluo-
rescent antibody (IFA) testing (12) of his serum at CDC
showed that his IFA titers had risen from <1:8 (i.e., negative)
pretransplant to 1:1024 posttransplant (Table). Nested poly-
merase chain reaction (PCR) analysis of blood, using primers
described previously (13), was positive for B. microti DNA.
Results of pre- and posttransplant serologic testing for anti-
bodies to Borrelia burgdorferi, Ehrlichia chaffeensis, and the
agent of human granulocytic ehrlichiosis (14), performed at
the New York State Department of Health, were negative
(Table).
On November 10, therapy with quinine (650 mg orally, 3
times a day) and clindamycin (400 mg intravenously, 4 times a
day) was begun. His course was complicated by worsening
parasitemia (maximum documented level was 3.1% on
November 13), hemolytic anemia (hemoglobin concentration
decreased from 11.4 g/dL on November 9 to a minimum value
of 7.4 g/dL on November 15), acute renal failure (creatinine
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value rose from 1.4 mg/dL on November 9 to a maximum
level of 3.3 mg/dL on November 15), and adult respiratory dis-
tress syndrome requiring mechanical ventilation.
On November 14, his therapy for babesiosis was changed
to azithromycin (500 mg intravenously, once a day) and atova-
quone (750 mg orally, 2 times a day) because of severe tinni-
tus, increased level of parasitemia (3.1% on November 13),
and ongoing fever (maximum of 38.6°C). On November 21,
he was afebrile and had a negative blood smear. He was dis-
charged on November 25. Therapy with azithromycin (250 mg
orally, once a day) and atovaquone (750 mg orally, 2 times a
day) was continued for a total of 2 weeks on these drugs. The
patient remained well as of August 2001. 
Investigation of Blood Donors
We traced the donors of the 32 PRBC units transfused dur-
ing the patient’s hospitalization in New York City. For two
donors, the transfused units had associated frozen components
(i.e., FFP) available that could be retrieved; for six donors,
PRBC units from subsequent donations were available for test-
ing. The blood products from these eight donors were negative
for antibodies to B. microti by IFA testing. 
The other 24 donors submitted blood for testing. On March
12, 2001, the New York State Department of Health laboratory
reported that one donor had an IFA titer of 1:256, which was
confirmed by CDC (Table). The other 23 donors had negative
IFA titers. The blood specimen from the implicated donor had
been obtained on February 28, 2001, 5 months after the origi-
nal blood donation on September 22, 2000. The PRBC unit
was transfused on October 1, 2000, and the patient first
reported fever on November 5, 2000. Thus, the incubation
period for the case of babesiosis was estimated to be 35 days.
CDC performed additional diagnostic testing on the implicated
donor’s blood. PCR analysis was negative for B. microti DNA,
and parasitemia did not develop in hamsters injected with his
blood (Table). The donor was thus implicated on the basis of
serologic rather than parasitologic data. Given that he was not
treated for babesiosis, the negative results of the parasitologic
testing suggest that the donor’s infection cleared spontane-
ously. However, he could have had low-level or intermittent
parasitemia not detected by the parasitologic testing.
After the donor was implicated, other components from
the index donation were investigated. No other patients
received blood components from the implicated donation. The
only other component identified was one unused unit of FFP,
which already had been destroyed. The donor’s only previous
donation was 1 year before the index donation. The lone recip-
ient from that donation remained asymptomatic but was not
tested for evidence of B. microti infection. 
Investigation of Implicated Donor
The implicated donor, a 45-year-old spleen-intact man
from Westchester County, New York, had been asymptomatic
the year before his blood donation. In 2000, he had visited
New Haven County, Connecticut, in May; Long Island (Jones
Beach), New York, in July and August; and Narragansett,
Table. Results of serologic testing, polymerase chain reaction analyses, and hamster injection for specimens from the case-patient with 
babesiosis and the implicated blood donora
Date of specimen Timing of specimen Test Result of testing
Case-patient
September 21, 2000 Pretransplant Babesia microti IFA  <1:8b
November 14, 2000 Posttransplant B. microti IFA  1:1024
November 14, 2000 Posttransplant B. microti PCR  Positive
September 21, 2000 Pretransplant Agent of HGE, IgMc  Negative
November 14, 000 Posttransplant Agent of HGE, IgM  Negative
September 21, 2000 Pretransplant Agent of HGE, IgG  Negative
November 14, 2000 Posttransplant Agent of HGE, IgG  Negative
September 21, 2000 Pretransplant Ehrlichia chaffeensis IFA  Negative
November 14, 2000 Posttransplant E. chaffeensis IFA Negative
September 21, 2000 Pretransplant Lyme ELFA  Negative
November 14,2000 Posttransplant Lyme ELFA  Negative
Implicated blood donor (tested approximately 
5 months after donation)
February 28, 2001 Postdonation Babesia microti IFA 1:256
February 28, 2001 Postdonation B. microti PCR Negative
February 28, 2001 Postdonation Hamster inoculationd Negative
aIFA, indirect fluorescent antibody; PCR, polymerase chain reaction; HGE, human granulocytic ehrlichiosis; Ig, immunoglobulin; ELFA, enzyme-linked fluorescence assay. 
bBabesia microti IFA= 1:8=negative.
cIgM and IgG immunoblots for HGE. 
dTwo hamsters were each inoculated intraperitoneally on April 3 with 0.75 mL of blood obtained on February 28. Giemsa-stained smears were made from hamster blood obtained 
twice weekly, for 8 weeks, by tail snip. The hamsters did not become demonstrably parasitemic.DISPATCHES
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Rhode Island, in July. He worked outdoors and gardened as a
hobby. He did not recall a tick bite. 
Investigation of Heart Donor
The heart donor was a 54-year-old woman who died after a
cerebrovascular accident. She had lived and worked in New
York City and had had no symptoms consistent with babesiosis
before the stroke. While hospitalized, she had remained afe-
brile with a normal complete blood count and renal function.
No serum from her was available for B. microti IFA testing.
Conclusions
We conclude that our patient, who lived in New Jersey,
acquired babesiosis through transfusion of PRBC in New York
City after a cardiac transplant. The evidence consistent with
this conclusion includes the following: he did not recall a tick
bite (most patients with babesiosis do not [9–11]); he did not
spend much time outdoors; he was seronegative by B. microti
IFA 5 days before his heart transplant and markedly seroposi-
tive when babesiosis was diagnosed 45 days after his trans-
plant; he received blood from a donor with a B. microti IFA
titer of 1:256; and he became symptomatic during the typical
two 8-week incubation periods for transfusion-transmitted B.
microti infection (7). 
Other possible modes of transmission seem much less
likely. We doubt he became infected through a blood transfu-
sion in New Jersey; he was seronegative by B. microti IFA 4.5
weeks after the New Jersey transfusions. We also doubt that he
acquired his infection while recuperating after his heart trans-
plant; his limited outdoor activities made tick exposure
unlikely. 
More than 40 cases of transfusion-transmitted babesiosis
have been reported in the United States. Most infections have
been acquired through PRBC transfusions, but cases have also
resulted from transfusion of frozen-deglycerolized red cell
units (15,16) and platelet units (6,7) (the latter have residual
red cells). Two previous cases of B. microti infection have
been reported in solid-organ transplant patients, although no
cases acquired through transplantation per se have been
reported (17,18). 
We initially treated our patient with quinine and clindamy-
cin but later changed the regimen to atovaquone and azithro-
mycin. A recent clinical trial demonstrated that the
combination of atovaquone and azithromycin is as effective as
quinine and clindamycin for the treatment of babesiosis in
patients without life-threatening disease (such patients were
excluded from this trial) (19). In our patient, who was criti-
cally ill, immunosuppressed, and a solid-organ transplant
recipient, the combination of atovaquone and azithromycin
was effective therapy. 
Babesiosis should be considered in the differential diagno-
sis of transplant patients who have fever and hemolytic ane-
mia, and blood transfusion should be considered as one of the
possible means of acquisition of infection. Solid-organ trans-
plant recipients may receive many blood products, which
necessitates an extensive investigation to implicate a donor.
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